Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0238 | 0.0861 | 0.043 |
Chlamydia trachomatis | glutamine binding protein | 0.0171 | 0 | 0.5 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0171 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0171 | 0 | 0.5 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0171 | 0 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0948 | 1 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0234 | 0.0801 | 0.0436 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.0287 | 0.1491 | 0.1089 |
Schistosoma mansoni | glutamate receptor NMDA | 0.083 | 0.8484 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0763 | 0.7623 | 0.7511 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0171 | 0 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0287 | 0.1491 | 0.1089 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0763 | 0.7623 | 0.7511 |
Loa Loa (eye worm) | hypothetical protein | 0.0287 | 0.1491 | 1 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.071 | 0.6933 | 0.6789 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0171 | 0 | 0.5 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.024 | 0.088 | 1 |
Echinococcus granulosus | glutamate receptor NMDA | 0.071 | 0.6933 | 0.6789 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 79 % | Irreversible inhibition against Norepinephrine (NE)-induced response in rat vas deferens with benextramine (BHC) as standard at a concentration of 2 x 10e-5 M | ChEMBL. | 2885418 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.